150
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond

&
Pages 1205-1216 | Published online: 05 Aug 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shilpa Bhatia, Luni Emdad, Swadesh K Das, Hossein Hamed, Paul Dent, Devanand Sarkar & Paul B Fisher. (2014) Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. Expert Opinion on Investigational Drugs 23:4, pages 489-500.
Read now

Articles from other publishers (12)

Ramon MartinezIIIIII, Weiliang Huang, Heather Buck, Samantha Rea, Amy E. Defnet, Maureen A. Kane & Paul Shapiro. (2022) Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors. ACS Omega 7:4, pages 3293-3311.
Crossref
Abeer Alharbi, Yuxuan Zhang & John Parrington. (2021) Deciphering the Role of Ca2+ Signalling in Cancer Metastasis: From the Bench to the Bedside. Cancers 13:2, pages 179.
Crossref
Rebaz Ahmed, Ranganayaki Muralidharan, Akhil Srivastava, Sarah E. Johnston, Yan D. Zhao, Suhendan Ekmekcioglu, Anupama Munshi & Rajagopal Ramesh. (2021) Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells. Cancers 13:2, pages 166.
Crossref
Masanari Umemura, Erdene Baljinnyam, Stefan Feske, Mariana S. De Lorenzo, Lai-Hua Xie, Xianfeng Feng, Kayoko Oda, Ayako Makino, Takayuki Fujita, Utako Yokoyama, Mizuka Iwatsubo, Suzie Chen, James S. Goydos, Yoshihiro Ishikawa & Kousaku Iwatsubo. (2014) Store-Operated Ca2+ Entry (SOCE) Regulates Melanoma Proliferation and Cell Migration. PLoS ONE 9:2, pages e89292.
Crossref
Luca Grieco, Laurence Calzone, Isabelle Bernard-Pierrot, François Radvanyi, Brigitte Kahn-Perlès & Denis Thieffry. (2013) Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision. PLoS Computational Biology 9:10, pages e1003286.
Crossref
Tetyana Tegnebratt, Li Lu, Lucy Lee, Valerie Meresse, Jean Tessier, Nobuya Ishii, Naoki Harada, Pavel Pisa & Sharon Stone-Elander. (2013) [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models. EJNMMI Research 3:1, pages 67.
Crossref
R.M. Martí, A. Sorolla & A. Yeramian. (2012) New Therapeutic Targets in Melanoma. Actas Dermo-Sifiliográficas (English Edition) 103:7, pages 579-590.
Crossref
R.M. Martí, A. Sorolla & A. Yeramian. (2012) Nuevas dianas terapéuticas en el melanoma. Actas Dermo-Sifiliográficas 103:7, pages 579-590.
Crossref
Yun-Ki Kim, Soon Kil Ahn & Michael Lee. (2012) Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152. Cancer Letters 320:2, pages 215-224.
Crossref
Young-A. Song, Young-Lan Park, Kyu-Yeol Kim, Eun Myung, Cho-Yun Chung, Sung-Bum Cho, Wan-Sik Lee, Young-Do Jung, Sun-Seog Kweon & Young-Eun Joo. (2012) RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Pathology International 62:2, pages 127-136.
Crossref
Changxue Lu & Sheue-yann Cheng. (2011) Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids.
Crossref
Mark D. Vincent. 2011. 283 350 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.